Solaris Endovascular Receives FDA Breakthrough Device Designation for Solaris DE™
Solaris Endovascular has received FDA Breakthrough Device Designation for its new Drug-Eluting Covered Stent, Solaris DE™, which utilizes a sirolimus eluting platform.
DALLAS, TX, UNITED STATES, May 5, 2026 /EINPresswire.com/ — Solaris Endovascular, Inc, a medical device company focused on next-generation endovascular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough …